The Shotlee Journal
Browse Shotlee articles about Ozempic.
Showing 9 / 1088 Ozempic articles
New regulations warn that GLP-1 medication users could face significant fines if side effects impair driving. Here is the complete guide to staying safe and compliant.
Clinical trials for the triple-agonist Retatrutide show promising weight loss, but 11% of high-dose participants dropped out due to side effects.
Many women starting GLP-1 therapies experience significant weight loss, only to find their menopausal symptoms—like hot flashes and sleep issues—intensify. This phenomenon is often overlooked because rapid fat loss directly interacts with the body's declining estrogen production, creating a complex hormonal shift that many prescribers are not trained to address.
Eli Lilly's retatrutide is making waves in the weight loss landscape. This comprehensive look delves into its Phase III results, comparing it to existing treatments and exploring its potential impact on obesity management.
As GLP-1 medications gain popularity for weight loss and diabetes management, understanding their impact on nutrient absorption is crucial. This article explores the link between these powerful drugs and the rising demand for supplements, offering insights from medical professionals and research.
Recent lawsuits are raising serious questions about the potential for GLP-1 medications, widely used for diabetes and weight loss, to cause a rare but devastating eye condition known as NAION, leading to permanent vision loss. This article delves into the allegations, scientific evidence, and ongoing legal proceedings.
Eli Lilly's experimental drug retatrutide has demonstrated unprecedented weight loss results in a pivotal trial. This article delves into its mechanisms, efficacy, safety, and how it stacks up against current leading weight loss medications like Ozempic and Wegovy.
Eli Lilly's experimental drug Retatrutide is making waves with unprecedented weight loss results in clinical trials, potentially setting a new benchmark in obesity treatment. This comprehensive look examines its efficacy, mechanism, and comparison to existing GLP-1 and GIP agonists.
Could the same medications revolutionizing weight loss and diabetes management also hold the key to treating addiction? Emerging research suggests GLP-1 receptor agonists may play a significant role.
